ArticleFrontiers in endocrinology2025
Association between atherogenic index of plasma and future cardiovascular disease risk in middle-aged and elderly individuals with cardiovascular-kidney-metabolic syndrome stage 0-3.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Association between the atherogenic index of plasma and prognosis in kidney transplant recipients: a retrospective cohort study.International urology and nephrology · 2026Article
- Effectiveness of plasma atherogenic index as a predictor of cardiovascular risk in patients with metabolic syndrome and related cardiometabolic conditions: a systematic review.Cardiovascular endocrinology & metabolism · 2026Review
- Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiometabolic multimorbidity in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Association between the atherogenic index of plasma trajectory and risk of cardiovascular diseases among hypertensive patients: a prospective cohort study.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
- Triglyceride glucose index and atherogenic index of plasma predict rapid kidney function decline in cardiovascular-kidney-metabolic syndrome: the first longitudinal evidence from CHARLS.European journal of medical research · 2025Article
- Association of cumulative changes in atherogenic index of plasma and its obesity-related derivatives with cardiovascular disease: emphasis on incremental risk of diabetes status.Cardiovascular diabetology · 2025Article
- Association between the cardiometabolic index and cardiovascular disease risk in patients with cardiovascular-kidney-metabolic syndrome: a cohort study.BMC cardiovascular disorders · 2025Article
- Exploring Potential Causality and Molecular Mechanisms between Heart Failure and Renal Failure: Insights from Mendelian Randomization Studies, the MIMIC-IV Database and the Gene Expression Omnibus Database.Journal of vascular research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) is strongly correlated with plasma atherogenic index (AIP); however, there is limited literature exploring the association between trajectories of change in AIP and the risk of CVD. This study aimed to investigate whether changes in AIP are associated with CVD in individuals with cardiovascular-kidney-metabolic (CKM) syndrome stage 0-3. Methods: Data were sourced from the China Health and Retirement Longitudinal Study (CHARLS), aimed to compile high-quality microdata on individuals and households aged 45 and older in China. Change in AIP from 2012 to 2015 were classified employing K-means clustering analysis. Logistic regressions were employed to assess the association between different AIP change clusters and cumulative AIP and CVD incidence. Additionally, restricted cubic spline (RCS) regression was conducted to further evaluate the underlying linear relationship between cumulative AIP and CVD. Subgroup analyses were applied to verify the influence of confounding variables on the relationship between AIP and CVD. Weighted quantile sum (WGS) regressions were utilized to offer a comprehensive assessment of the overall effect. Results: Out of 4,525 participants, 578 (12.77%) ultimately developed CVD within three years. Compared to cluster 1, which served as the best control for AIP, the odds ratio (OR) was 1.29 (1.02-1.62) for cluster 2, 1.33 (1.04-1.71) for cluster 3 and 1.35 (0.98-1.85) for cluster 4 after adjusting for several confounding variables. Categorizing the cumulative AIP into quartiles revealed an ascending trend (P for trend = 0.014). RCS regression disclosed a linear relationship between cumulative AIP and CVD. Further subgroup analyses revealed variations in these correlations modified by gender and Hukou status. WQS regression analysis highlighted the significance of triglyceride in the pathogenesis of CVD. Conclusions: Significant changes in AIP are independently associated with the elevated risk of CVD in adults aged > 45 with CKM syndrome stage 0-3. Monitoring long-term fluctuations in AIP may aid in the early identification of individuals at high risk for CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.